Indian stocks: Visit www.stage2stocks.com →

Aprea Therapeutics, Inc.

Stage 1 · Basing · week 7

As of Oct 22, 2026, Aprea Therapeutics is in Stage 1, the basing phase, now in week 7 (since Sep 10, 2026). It closed at $0.54, 64.6% below its 52-week high and below its 200-day average, which is falling.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. More about the company

$0.54
-3.27% today
$6.8M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Steady

Edge

—

Is APRE early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 15w
S4 19w
S4 17w
S4 35w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 1w → S1 13w → S2 1w → S3 4w → S4 1w → S3 1w → S2 15w → S3 8w → S4 19w → S1 10w → S4 2w → S1 4w → S4 17w → S1 6w → S4 35w → S1 10w → S4 10w → S1 6w current
Total tracked: 164 weeks across 18 stage runs.

APRE among Biotechnology413th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…413APREStage 1 · wk 717−30.5%
vs 52W High
-64.6%
$0.53 lo$1.53 hi
64.6% below 52W high
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 7
1w13w26w
Week 7, early base
How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.
vs 200 DMA
-29.2%
200 DMA: $0.77 · sloping down
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
0.36x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-30.5%
3M
-14.2%
6M
-38.7%
YTD
-36.5%
1Y
-64.1%
Scan Membership
Breakout Watch
Latest: 2024-01-16
4 appearances in last 60 days. First seen: 2020-07-20.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S1
Wk 7 · Vol 0.36x
2026-10-21S1
Wk 6 · Vol 0.23x
2026-10-20S1
Wk 6 · Vol 1.04x
2026-10-19S1
Wk 6 · Vol 0.58x
2026-10-16S1
Wk 6 · Vol 0.46x
2026-10-15S1
Wk 6 · Vol 0.19x
2026-10-14S1
Wk 5 · Vol 0.21x
2026-10-13S1
Wk 5 · Vol 0.40x
2026-10-12S1
Wk 5 · Vol 0.34x
2026-10-09S1
Wk 5 · Vol 0.20x
2026-10-08S1
Wk 5 · Vol 0.70x
2026-10-07S1
Wk 4 · Vol 0.74x
Moving averages & range
50 DMA
$0.72
200 DMA
$0.77
52W High
$1.53
52W Low
$0.53
5D Low
$0.53
Resistance levels (recent highs)
20d High
$0.77
60d High
$0.98
120d High
$0.98
250d High
$1.45
Next resistance
+42.1%
to 20d High
ROE
-46.1%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 0.2

Aprea Therapeutics: quick answers

What stage is Aprea Therapeutics in?

As of Oct 22, 2026, Aprea Therapeutics (APRE) is in Stage 1, the basing phase. It entered Stage 1 on Sep 10, 2026 and is in week 7. What the four stages mean

Is Aprea Therapeutics in an uptrend?

Not yet. Aprea Therapeutics is in Stage 1, a base that can come before an uptrend. It trades 29.2% below its 200-day average, which is falling.

How far is Aprea Therapeutics from its 52-week high?

Aprea Therapeutics closed at $0.54 on Oct 22, 2026, 64.6% below its 52-week high of $1.53. Its 52-week low is $0.53.

How has Aprea Therapeutics performed over the past year?

As of Oct 22, 2026, Aprea Therapeutics is down 64.1% over the past year and down 36.5% so far in 2026.

Which sector and industry is Aprea Therapeutics in?

Aprea Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.